[1] |
Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America[J]. Crit Rev Microbiol, 2010,36(1):1-53.
doi: 10.3109/10408410903241444
URL
|
[2] |
Kim J, Sudbery P. Candida albicans, a major human fungal pathogen[J]. J Microbiol, 2011,49(2):171-177.
doi: 10.1007/s12275-011-1064-7
URL
|
[3] |
Wang H, Xiao M, Chen SC, et al. In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study[J]. J Clin Microbiol, 2012,50(12):3952-9359.
doi: 10.1128/JCM.01130-12
pmid: 23035204
|
[4] |
Nobile CJ, Johnson AD. Candida albicans biofilms and human disease[J]. Annu Rev Microbiol, 2015,69:71-92.
doi: 10.1146/annurev-micro-091014-104330
URL
|
[5] |
Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem[J]. Clin Microbiol Rev, 2007,20(1):133-163.
pmid: 17223626
|
[6] |
Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment[J]. Am J Med, 2012,125(1 Suppl):S3-S13.
|
[7] |
Cannon RD, Lamping E, Holmes AR, et al. Candida albicans drug resistance another way to cope with stress[J]. Microbiology(Reading), 2007,153(Pt 10):3211-3217.
|
[8] |
Badiee P, Alborzi A. Susceptibility of clinical Candida species isolates to antifungal agents by E-test, Southern Iran: a five year study[J]. Iran J Microbiol, 2011,3(4):183-188.
|
[9] |
Lloyd DH. Alternatives to conventional antimicrobial drugs: a review of future prospects[J]. Vet Dermatol, 2012,23(4):299-304,e59-e60.
doi: 10.1111/j.1365-3164.2012.01042.x
URL
|
[10] |
Rani N, Sharma A, Gupta GK, et al. Imidazoles as potential antifungal agents: a review[J]. Mini Rev Med Chem, 2013,13(11):1626-1655.
doi: 10.2174/13895575113139990069
URL
|
[11] |
岳聪聪, 苏冰, 张晓雪, 等. 两种方法检测白色念珠菌对氟康唑的体外药敏结果比较及耐药原因分析[J]. 延安大学学报(医学科学版), 2018,16(2):61-64.
|
[12] |
Chen L, Wang Z, Liu L, et al. Cinnamaldehyde inhibits Candida albicans growth by causing apoptosis and its treatment on vulvovaginal candidiasis and oropharyngeal candidiasis[J]. Appl Microbiol Biotechnol, 2019,103(21-22):9037-9055.
doi: 10.1007/s00253-019-10119-3
pmid: 31659418
|
[13] |
Zhang M, Yan H, Lu M, et al. Antifungal activity of riba-virin used alone or in combination with fluconazole against Candida albicans is mediated by reduced virulence[J]. Int J Antimicrob Agents, 2020,55(1):105804.
doi: 10.1016/j.ijantimicag.2019.09.008
URL
|
[14] |
Cowen LE, Steinbach WJ. Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance[J]. Eukaryot Cell, 2008,7(5):747-764.
doi: 10.1128/EC.00041-08
pmid: 18375617
|
[15] |
Xiang MJ, Liu JY, Ni PH, et al. Erg11 mutations associa-ted with azole resistance in clinical isolates of Candida albicans[J]. FEMS Yeast Res, 2013,13(4):386-393.
|
[16] |
Dominianni SJ, Yen TT. Oral hypoglycemic agents. Discovery and structure-activity relationships of phenacylimi-dazolium halides[J]. J Med Chem, 1989,32(10):2301-2306.
pmid: 2795602
|
[17] |
Chopra PN, Sahu JK. Biological significance of imidazole-based analogues in new drug development[J]. Curr Drug Discov Technol, 2020,17(5):574-584.
doi: 10.2174/1570163816666190320123340
URL
|
[18] |
Sharma S, Gangal S, Rauf A. Convenient one-pot synthesis of novel 2-substituted benzimidazoles, tetrahydroben-zimidazoles and imidazoles and evaluation of their in vitro antibacterial and antifungal activities[J]. Eur J Med Chem, 2009,44(4):1751-1757.
doi: 10.1016/j.ejmech.2008.03.026
URL
|